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Abstract: A multifunctional branched co-polymer was synthesized by Reversible Addition- 
Fragmentation Chain Transfer polymerisation (RAFT) of poly (ethylene glycol) diacrylate (PEGDA 
Mn=575) and poly (ethylene glycol) methyl methacrylate (PEGMEMA Mn=500) at 50:50 molar ratio. 
Proton nuclear magnetic resonance spectroscopy (1H NMR) confirmed a hyper branched molecular 
structure and a high degree of vinyl functionality. An in situ cross-linkable hydrogel system was created 
via a “click” thiol-ene type Michael addition reaction of vinyl functional groups from this copolymer with 
thiol-modified hyaluronic acid, a natural immunoneutral polysaccharide. Further encapsulation with 
antimicrobial silver sulfadiazine (SSD) was conducted to create an advanced antimicrobial wound care 
dressing. This hydrogel demonstrated a sustained antibacterial activity against the bacteria 
Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli at a moderate level comparing to 
the direct topical application of SSD. In addition, in vitro toxicology evaluations demonstrated that this 
hydrogel, with low concentrations of SSD supported the survival of embedded human adipose derived 
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stem cells (hADSC’s) and inhibited growth of mentioned pathogens. This study demonstrates that this 
hydrogel encapsulated with a low concentration (1.0% w/v) of SSD can be used as a cell laden gel system 
with the ability to inhibit growth of pathogens without posing an unacceptable threat towards ADSC’s. 
 
1. Introduction 
In our quest to develop an advanced wound care dressing, hydrogels with multiple functions were 
investigated. Highly branched copolymers have been studied over the past decade while our research 
focus is on their applications in medicine and the wound care market including hydrogels. Pathogens are 
proving more difficult to eradicate as bacteria continue to develop worrying resistance towards 
antibiotics.  This bacterial resistance is growing daily in both community and hospital settings and is 
leading to increased mortality and morbidity1. For this reason, new innovative approaches, including 
reinvigoration of tried and tested agents with novel delivery must be investigated to prevent infection and 
encourage wound repair. 
Hydrogel technology is a rapidly advancing field with a wide range of applications2 3 4 . Hydrogels are 
composed of a high percentage of water which provides a perfect moist environment for tissue 
regeneration5 while also preventing contraction of the wound. Additionally, these hydrogel systems can 
be engineered to deliver cells and drugs6. This proposed moist environment can provide a rich supply of 
white blood cells, enzymes, cytokines and growth factors7. Primarily released enzymes from white blood 
cells can cause selective autolytic debridement of necrotic tissue8. Unfortunately this moist environment 
can also provide an ideal site for the colonization of bacteria 9and therefore hydrogels should be applied 
with a synergistic antimicrobial agent10. 
It is clear that the natural defence systems of organisms are highly advanced; nonetheless, the 
regeneration process is often delayed and hampered by a number of factors11.  The forefronts include 
infection and an inappropriate wound environment. Concerns in the treatment of wounds, and indeed 
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many other pathogenic conditions currently rest with the ever threatening development of bacterial 
resistance12. Worldwide, bacterial resistance has increased dramatically over the past few years13 and is 
recognised as a highly significant medical challenge. Many bacterial species are now resistant to 
antibiotics and some Gram-negative bacteria, especially the Pseudomonas aeruginosa species have 
developed resistance to most or all available antibiotics14. Furthermore, since the year 2000 only three 
new classes of antibiotics have been introduced to the market for human use15. Despite the certain need 
for novel antibiotics without cross-resistance issues, research and development has not yet delivered16, 
thus failing to provide an answer to the fast emergence and spread of these dangerous bacteria.  It is the 
focus of this work to develop an approach that is bio-medically engineered with strategic design to 
counteract the fast development of bacterial resistance that in the past has rendered many treatments 
obsolete. Novel treatments are clearly slow to develop and achieve regulatory approval;  thus it has been 
the aim of this research to re-invigorate use of an age-old antimicrobial agent, such as silver sulfadiazine 
(SSD), in medical wound care dressings/delivery for a lasting more effective antibacterial dressing with 
improved stimulation of wound regeneration in combination with cell therapy. Proof of concept research 
finding with this antibacterial agent will demonstrate the potential for this system being used in 
combination with many other antibacterial agents. 
A recent review into the mechanisms of bacterial resistance has detailed three important cases including 
E. coli resistance to third-generation cephalosporins, the emergence of vancomycin-resistant S. aureus, 
and multidrug resistance in P. aeruginosa 17 . Both S. aureus and P. aeruginosa are recognised as 
ESKAPE pathogens emphasizing their capacity to “escape” from common antibacterial treatments18. 
Research suggests that these bacteria are developing resistance through a host of mechanisms19. Aside 
from bacteria being intrinsically resistant to ≥1 class of agents, they may also acquire their resistance by 
mutation or acquisition of resistance genes from other organisms. These can enable a bacterium to 
produce an enzyme to supress the antibacterial agent, to prevent an agent reaching its target, to change its 
target site or to produce an alternative metabolic pathway to bypass the action of the drug entirely20. This 
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suggests that a long term effective treatment will need to employ a range of inhibitory mechanisms. This 
will effectively prolong the development of resistance by ensuring that development of one resisting trait 
will not be sufficient to prevent bacteria death. 
The anti-bacterial effectiveness of silver has a long history. It has been used for at least six millennia to 
prevent microbial infections. The first known record of silver nitrate being used as a medical agent was 
reported by Gabor in the year 702 and in the year 980 A.D. as a blood purifier and to treat palpitations of 
the heart21. By the 1800s it was taken as common practice (for wealthy) to store wine, water and milk in 
silver containers to keep them fresh for longer. Nano-Ag particles and their mechanisms of inhibition are 
a topic of disputed interest but have demonstrated the ability to destabilize the outer membrane, collapse 
the plasma membrane potential and deplete the levels of intracellular ATP of E. coli22. These silver based 
agents are particularly effective against a wide range of pathogens23 and it remains particularly difficult 
for bacteria to develop resistance to the action of silver due to the range of inhibitory mechanisms 
evoked24. It is well known that silver ions and silver based compounds are highly effective against micro-
organisms exhibiting potent antibacterial activity on as many as 16 species of bacteria25.    
SSD is a similar drug to silver nano particles in its mechanism of inhibition and is typically delivered in a 
1% cream or aqueous suspension. It has proved extremely effective for burn wounds to the extent that it is 
the current gold standard treatment used to treat serious burn wounds but presents opportunity for cross 
application in other high infection risk areas. This is a highly efficient inhibitor of microbial growth 
belonging to a family of drugs called sulfa antibiotics. Silver is complexed to propylene glycol, steryl 
alcohol and isopropyl myrislate. This is mixed with the antibiotic Sulfadiazine to achieve a combined 
formulation that is highly effective. By substituting a silver atom for a hydrogen atom in the sulfadiazine 
molecule it results in a combination of the inhibitory action of the silver with the anti-bacterial effect of 
the sulfadiazine26 27. This antibacterial agent is appropriate for hydrogel incorporation in its powder form. 
It is relatively inexpensive, easy to apply, well tolerated by host cells and has good activity against most 
pathogens but more importantly it employs a range of mechanisms which makes it difficult to develop 
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resistance against28 29. Interest in these silver based antibacterial agents has recently been rejuvenated, 
mainly due to the spread of methycillin-resistant S. aureus (MRSA) and the associated reduction in 
effective antibiotics.  This silver sulfadiazine combination is highly effective which can be explained by 
the strong bonding that occurs between this silver compound with DNA which differs from silver salts 
alone. Furthermore this silver sulfadiazine combination has an increased effectiveness on disrupting the 
bacterial wall. Therefore, SSD has been selected for this application due to the broad spectrum of activity 
and the significantly lower propensity to induce microbial resistance than other antibiotics30. However, a 
high dosage of SSD through topical administration could be toxic and cause side effects. 
We hypothesise that the encapsulation of SSD within a PEG based 3D hydrogel scaffold can provide an 
enhanced wound regeneration environment with controlled release of an antimicrobial agent and ease the 
need for improved anti-resistant solutions. This advanced antimicrobial hydrogel can be used for delivery 
of therapeutic cells while preventing cell death caused by infection. In this work, a hydrogel was created 
by combining our in situ crosslinkable copolymer with thiol modified (SH) hyaluronic acid (HA). 
Hyaluronan or hyaluronic acid (HA) is a linear d-glucuronic acid and N-acetyl-D-glucosamine 
copolymer32 and is known as a good biopolymer for many biomedical applications33. This report presents 
experimental data on the synthesis of hydrogels, loading of SSD, antibacterial disk diffusion tests and cell 




Figure 1. Preparation of highly branched polymer from the monomers PEGDA and PEGMEMA using 
the RAFT polymerisation technique initiated by ACHN. The highly branched polymer structure contains 
multiple vinyl functional groups, which will react with thiol functional groups in HA-SH via thio-ene 
addition reaction mechanism, to form cross-linked hydrogels. 




Silver Sulfadiazine (SSD) Powder (98%), Poly (ethylene glycol) methyl ether methacrylate (PEGMEMA, 
𝑀𝑛= 500 g mol-1), Poly (ethylene glycol) diacrylate (PEGDA, 𝑀𝑛 = 575 g mol-1) and the initiator: 1, 1′-
Azobis cyclohexanecarbonitrile (ACHN) were purchased from Sigma-Aldrich. The RAFT agent was 
synthesised according to published method34. Thiol-modified hyaluronic acid (HA-SH) was purchased 
from Glycosan. Bacterial strains S. aureus, P. aeruginosa and E. coli were supplied by the Microbiology 
group at NUI Galway. 
2.2. Methods 
2.2.1. Synthesis of PEGDA-PEGMEMA Hyperbranched Copolymer 
The multivinyl hyperbranched PEGDA-PEGMEMA co-polymer was synthesized via RAFT 
polymerisation from the monomers poly (ethylene glycol) diacrylate (PEGDA Mn=575) and poly 
(ethylene glycol) methyl methacrylate (PEGMEMA Mn=500) at 50:50 molar ratio according to previous 
published method34  (Figure 1). PEGDA-PEGMEMA co-polymer was analysed using 1H NMR to 
confirm its structure and composition and using GPC to obtain its Mw and PDI. The data can be found in 
the supporting information (SI).  
2.2.2 Preparation of Hydrogel Samples 
A 10% PEGDA-PEGMEMA copolymer solution was prepared using 1X PBS solution. 150µL of this 
polymer solution was transferred into separate eppendorfs under sterile conditions. SSD was measured by 
weight in its powder form and added to these eppendorfs to create concentrations of 0.0, 0.1, 1.0 and 
5.0% (see Table S4 in supplementary information). A volume of 150µL of thiol modified Hyaluronan 
was added to each Eppendorf creating a 1:1 copolymer: hyaluronan ratio in order to cross link and create 
hydrogels as shown in Figure 2. The addition of Hyaluronan was conducted to one eppendorf at a time, 
followed by rapid mixing and pipetting of 50µL samples to a clean sterile teflon surface under a flow 
hood. The samples formed globular shaped gels due to rapid cross linking within 2 minutes. This process 
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was repeated to create sufficient hydrogel (50µL) samples to conduct experiments in triplicate (n=3) for 
all SSD concentrations against three bacterial strains. These samples contained the SSD at concentrations 
of 0.0, 0.1, 1.0 and 5.0% w/v. 
 
Figure 2. Hydrogel sample preparation by cross linking of the vinyl groups on the polymer chains using a 
thiol modified hyaluronic acid. Polymer and thiol modified hyaluronic acid were represented by blue and 





2.2.2. Antibacterial Activity  
S. aureus, P. aeruginosa and E. coli were used as test organisms given their relevance as infectious agents 
and affinity to develop bacterial resistance. Bacteria were prepared and cultured in fresh Mueller Hinton 
Agar (MH). One loopful of bacteria was inoculated in a test tube of 5mL Luria Broth (LB) and grown, 
with shaking, at 37°C for 24 h. The optical density of these solutions was then measured using a Thermo 
Fisher Scientific Biomate 3 Spectrometer. These cultures were diluted in LB broth to an OD600 of 0.8 and 
moved to an incubator at 37oC with shaking at 250 RPM to re-grow bacteria to an OD600 of 0.1.  
A standard disk diffusion test was then performed in accordance to the protocol outlined in the Kirby-
Bauer test35. Mueller Hinton agar plates of 20 ml volume were prepared and 100µL samples of bacterial 
cultures were spread on plates. After 30 minutes incubation at room temperature, hydrogel samples 
containing varied SSD concentrations (0.0, 0.1, 1.0 and 5.0%) were added in triplicate to produce a total 
of 12 plates containing 36 hydrogel samples (3 bacterial strains x 4 SSD concentrations and n=3). All 
plates were incubated for 72 hours at 37oC, with zones of inhibition measured after 24, 48 and 72 hours 
using a Vernier Calliper’s. Measurement of zones was conducted by measuring three randomly orientated 
diameters from each hydrogel sample. Note, hydrogels containing SSD < 0.1% were not studied for 
antimicrobial activity as the literature suggests36 that concentrations below this nominal value are not as 
effective in maintaining antimicrobial environments. 
 
2.2.3. Diffusion Studies 
A simple release assay37 was conducted to investigate the release of these SSD particles over an extended 
period of time in PBS buffer. Initially the optimum wavelength for detection of particles was identified 
using spectroscopy (290nm) for assessing the presence of SSD particles. After identification of the 
appropriate wavelength, release studies were conducted on hydrogel samples containing SSD which were 
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prepared in triplicate (n=3) as previously described at the concentrations of 0.0, 0.1, 1.0 and 5% w/v. The 
release assay was conducted over 168 hours, time points taken at 2, 4, 21, 51 and 168 hours. 
 
2.2.4. Cytotoxicity Testing 
2.2.4.1. Cell Culture and Cell Count 
Adipose derived stem cells (ADSC’s) were passaged in a 1. 75𝑐𝑚3  culture flask and incubated at 37°C 
and 5% 𝐶𝑂2  with media changed every 2-3 days. The media used was Dulbecco’s Modified Eagles 
medium with Bovine Fetal 10% bovine serum and 1% penicillin streptomycin. 
Working in conjunction with standard protocol38 a cell count was conducted.  Taking a 96-well plate, 
20uL of Trypsin Blue was added to 3 of the wells. To the first well, 20uL of cell solution was added 
resulting in a 50% dilution. This was then diluted to 25% and 12.5% solutions by adding 20uL from the 
50% and 25% wells. The study determined a cell density of 2.8 𝑥 105 cells/ml. 
 
2.2.4.2. Cell Viability 
Cell viability was evaluated using the AlamarBlue assay following the protocol39 using freshly prepared 
(sterile) SSD encapsulated hydrogels. Experiments were conducted in triplicate to assure confidence. 
Hydrogels containing concentrations of 0.0, 0.005, 0.01 and 1.0% of SSD were synthesized for the 
experiment as explained previously. A concentration of 5.0% SSD was not tested as the literature reported 
that this level is too high for good cell viability40. 
Briefly the experiment was prepared by adding 50,000 cells and 2ml DMEM to each well (Total of 12 
wells per plate and labelled accordingly). In triplicate these gels were added to wells. Plates were all 




3.1. Preparation of Hydrogel Samples 
The hydrogel samples were prepared using a PEGDA-PEGMEMA hyperbranched copolymer with the 
composition of of 40:60 and molecular weight (Mn) of 15.5 KDa, which was synthesized using the feed 
molar ratio of PEGDA and PEGMEMA as 50:50 according to previously published methods (see SI for 
more information) This copolymer was crosslinked with thiol modified hyaluronic acid via thiol-ene click 
chemistry and loaded with SSD to create a matrix represented by Figure 3. These hydrogels (50µL) were 
prepared on sterile Teflon, which were uniform, soft and semi-transparent depending on the concentration 
of SSD used. Hydrogels exhibited a whitish colour with increased addition of SSD. All samples were 
easily removed from the Teflon tape and were globular in shape as shown in Figure 4. Hydrogels were 
structurally stable and kept their shape throughout process presenting little difficult in handling. Samples 
could be inverted on Teflon slide without detachment or shape changes, exhibiting good structural 
conformity and well defined cross linking network. 
 
Figure 3. SSD loaded crosslinked hydrogels. Prior to the addition of HA-SH to create crosslinked gels 
with PEG based hyperbranched copolymer, the copolymer was dissolved in water and mixed with SSD as 




Figure 4. (A) Hydrogel samples (40 - 50µl) with no loading and (B) Hydrogel (without loading) 
illustrating good workability and ease of use (no deformation in handling). (C) Hydrogel samples loaded 
with silver nano particles (SNP) (Black). Note, SNP loaded gels shown in image (C) as the black colour 
presents clear contrast. Silver sulfadiazine (SSD) encapsulated hydrogels present as  white hydrogels. 
 
3.2. Antibacterial Activity 
The zone of inhibition of bacteria was dependant on the diffusion of antibacterial agent as well as the 
SSD % presence. The zones of inhibition were clearly visible and are shown in Figure 5. When compared 
with silver nano particle (SNP’s) loading in the same concentration, the SSD samples proved more 
effective as inhibiting agents for combination with this particular hydrogel, some SNP loading and results 
are presented in supplementary information. These SSD loaded hydrogel samples displayed large zones 
of inhibition after a period of 24 h. These zones were inspected again at 48h and 72 h. The zones of 
inhibition did not change notably after these periods of time. Areas outside of the SSD diffusion showed 
high bacterial development notable by colour contrast in Figure 5. Colour images of plated bacteria are 
presented in the supplementary information, notice the light amber colour of (A) E. coli, the green of (B) 
P. aeruginosa, and the tan colour of (C) S. aureus in Figure S11. 
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Zones of inhibition are present in all SSD hydrogel samples with best results at 1% and 5% w/v 
concentrations. No zones of inhibition are present in control samples indicating the presence of SSD is 
required to prevent bacterial growth. This also demonstrates that the hydrogel allows diffusion of SSD 
and that SSD inhibits growth of each strain of bacteria tested with inhibition zones dependent on the 
diffusion behaviour. 
The study was repeated at increased concentrations of SSD, from 0.0%, 0.1 %, 1% to 5% in hydrogel 
samples. Test data from 1% and 5.0% proved to be equally efficient for inhibiting bacteria growth in 
terms of diffusion zones with no significant difference being observed. This suggests that a concentration 
of 1% SSD may be optimal for this particular hydrogel; however, diffusion limitations could be a 
contributing factor to inhibition zones. These results demonstrate that the use of SSD as an antibacterial 
agent is highly suitable in this hydrogel system since relatively low concentrations of 1% w/v SSD can 
readily diffuse in an acceptable timeframe. Inhibition of bacterial growth from 3 bacterial strains, 
including both Gram-positive and Gram-negative species, demonstrates good potential for this hydrogel 
to be used across a variety of bacterial pathogens. 
 
Figure 5. P. aeruginosa plated in agar containing uniform hydrogel samples loaded with silver 
sulfadiazine (SSD).  (A) 5.0% w/v, (B) 1.0% w/v, (C) 0.1% w/v, (D) 0.0% w/v. Note, hydrogel contrast is 
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Figure 6. Disk Diffusion zones after 72 hours on plated samples. Zone diameters were taken using a 
Vernier Callipers. Legend on right refers to w/v% of SSD per hydrogel sample.  Control hydrogels 
containing 0.0% SSD showed no zones of inhibition. Zones of inhibition for E. coli were smallest in 
diameter while SSD demonstrated inhibition in all cases where present. “1.0% SSD No hydrogel” 
represents SSD in aqueous solution plated on filter paper against bacterial samples without hydrogel 
carrier. 
 
From the data presented in Figure 5, it is clear that the presence of silver sulfadiazine inhibited growth of 
P. aeruginosa in all hydrogel samples excluding control sample containing no SSD. Note, image appears 
as though only one sample present in 0.0% concentration; however, hydrogel samples containing no SSD 






































Varying wt% SDD tested
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is clear that the presence of SSD in small amounts (ranging from 0.1% - 5.0% w/v) was sufficient in all 
studied cases to prevent bacterial growth. Bacterial strains: P. aeruginosa, S. aureus and E. coli were all 
studied and corresponding images presented in supporting information. Further studies will be undertaken 
to optimise the dosage with respect to inhibition of growth, SSD dispersion and cell viability. 
From the data presented in Figure 6, we observe the numerical quantification of the zones of inhibition of 
hydrogels with loadings of 0.0, 0.1, 1.0, 5.0 % w/v SSD and a positive control of 1.0% SSD in aqueous 
solution (no hydrogel) plated on filter paper. It is clear that the presence of SSD is required to cause 
bacterial inhibition. The negative control for this study is the hydrogel material containing 0.0% SSD 
loading which presents no zone of inhibition. The positive control for this study is the 1.0% SSD plated 
on filter paper which presents clearly defined zones of inhibition. When we consider the hydrogel loaded 
with SSD, we observe zones of inhibition that are comparable with those of the positive control. In all 
hydrogel cases, loading of SSD in dosage of 0.1% w/v presents zones of inhibition that are smaller than 
those of 1.0 and 5.0% w/v loadings. There was no significant difference in the zones of inhibition for 
1.0% and 5.0% w/v SSD loaded hydrogels when tested on bacteria S. aureus and P. aeruginosa. 
However, when hydrogels containing 1.0% and 5.0% SSD w/v loadings were tested on E. coli, the 5.0% 
w/v loading performed significantly better creating a larger zone of inhibition. It is noted that when this 
5.0% w/v SSD loaded hydrogel was tested against E. coli, it presents a zone of inhibition that is no 
greater in size than the zones of inhibition for 1.0% and 5.0% w/v loadings when tested against S. aureus 
or P. aeruginosa. This data suggests that E. coli may be more resistant to SSD than P. aeruginosa and S. 
aureus, thus requiring a larger dosage. 
 
3.3. Diffusion Studies 
  
Figure 7. Plot of silver sulfadiazine (SSD) release (absorbance) measured by UV-vis spectroscopy 






Figure 8: Plot of silver sulfadiazine (SSD) concentration in hydrogel sample against the square root of 
incubation time. 
Diffusion studies were undertaken as a function of absorbance over time using spectroscopy. Prior to 
diffusion study we identified the optimum wavelength for observing the presence of SSD. This study 
identified 290nm as the most appropriate wavelength for SSD identification. From the above diffusion 
studies (Figure 7) it is clear that the SSD is released from these hydrogel samples in a controlled and 
predictable manner (increasing concentrations of SSD results in a faster and higher level of SSD release). 
This SSD release study demonstrates an initial burst release of sufficient quantities of SSD to create 
strong adjacent antibacterial effect (particularly beneficial in infected wound cases). The same step leads 
to a slow prolonged release thereafter which would allow for good surface compatibility after the initial 
hours. This initial SSD burst release from the hydrogel also helps to avoid possible risks or potential of 
resistance and tolerance of bacterial cells to Ag 41 42 , which might occur in a constantly low silver 
releasing environment. 
Furthermore, increasing concentration of SSD within 0 – 5% w/v range does increase both the burst 







































hydrogels could be tuned for controlled release of predictable drug levels. Furthermore this study shows 
that this hydrogel system steadily releases SSD beyond a time point of seven days. A recent study found 
that three commonly used silver based dressings ( ACTICOAT™ Flex 3 (Smith & Nephew, Milan, Italy), 
Mepilex® Ag, Mölnlycke Health Care, Gallarate, Italy and ACTISORB® Silver 220 (Johnson & 
Johnson, Rome, Italy) guarantee sustained antimicrobial action for 3, 7 and 7 days respectively43. This 
demonstrates that our hydrogel system has potential to compete in this aspect with currently available 
silver based dressings.   
When SSD absorption is plotted against the square root of incubation time (Figure 8), a linear 
relationship is obtained (except for the initial stages of soaking). Figure 9 shows that the samples 
containing SSD present the trend-line with a high goodness of fit R2 values (0.896, 0.9901 and 0.9012). 
This is supported by literature44 and indicates that the release of SSD is controlled by inter-diffusion of 
the particles within the hydrogel45. This inter-diffusion is an important mechanism to confirm as it 
demonstrates that the release profile is tuneable and predictable based on the concentration of SSD loaded 




3.4. Cytotoxicity Investigation 
 













































Figure 11. Cell Viability Day 7. 0.005%, 0.01%, 1.0% silver sulfadiazine (SSD) hydrogels and 0.0% 
control hydrogel. 
In terms of the cell viability evaluation, hydrogel samples containing SSD of 0, 0.005, 0.01 and 1.0% w/v 
were tested using a standard Alamar blue assay on Adipose Derived Stem Cell’s (ADSC’s). The 
concentration of SSD was chosen at a lower level range for this study because it quickly became apparent 
that a higher concentration of SSD was toxic to these cells. Control hydrogel sample did not reduce the 
cell viability at day 1 (Figure 9), day 3 (Figure 10) and day 7 (Figure 11). Promisingly, the tests using 
SSD at 0.01 and 0.005% w/v dosage did not significantly reduce cell viability and cell proliferation either 
as observed by Day 7. However, the 1.0% w/v SSD loading resulted in a reduction in cell viability at Day 
1. This can be explained by the toxicity caused by the initial burst release of SSD upon initial introduction 
of hydrogel samples to cells. At Day 1 cell viability is reduced to 64.61%. However, at Day 3 (Cell 
viability: 71.42%) and Day 7 (Cell Viability: 62.18%). Cell viability figures did not drop significantly 
over prolonged time, suggesting a high burst release being a contributory factor to early cell mortality. 
Interestingly, hydrogel samples containing low levels of SSD (0.01 & 0.005%) in figure 11 & 12 
demonstrated increased cell proliferation at Day 3 and Day 7 with respect to the control hydrogel. This 





















whereby, an environment of sufficient antibacterial activity prevents bacterial growth without adversely 
impacting cellular activity thus providing a more ideal environment for cellular proliferation. 
4. Discussion 
One of the primary aims for the treatment of wounds is to prevent infection and then to promote 
proliferation of epithelial cells 46 . Therefore a wound dressing must find a balance between the 
antibacterial efficacy and cytotoxicity47. A moist environment is most suited for epithelialization and 
healing but this environment cannot become compromised with infection and therefore must actively 
inhibit bacterial growth. With this in mind, providing sufficient antibacterial efficacy to prevent bacterial 
growth but not to the extent that regenerative processes are hampered by aggressive treatments. New 
bioactive hydrogels such as cell laden hydrogels and gene delivery hydrogels require a good micro-
environment that is free of infection to function effectively in the treatment of hard-to-heal chronic 
wounds.  Therefore, antimicrobial hydrogel wound dressings should not simply aim to perform better 
than direct topical application of antimicrobial agent in terms of killing bacteria. It would be highly 
advantageous for the antimicrobial gel to contain low levels of antimicrobial agents (such as SSD) and 
release SSD in a controlled and sustained manner thus exhibiting low toxicity and minimized side effects. 
Moreover, antimicrobial hydrogels also have the advantage of being easily administered with a known 
dosage and forming gel in-situ. This antimicrobial gel can be used to deliver cells to the wound sites 
because of its cyto-compatibility. 
A poly (ethylene glycol) PEG based copolymer was developed for the purpose of the hydrogel synthesis 
owing to its controllability, reproducibility and suitable chemical structure for hydrogel formation48. A 
PEGDA-PEGMEMA copolymer and subsequently 3-D hydrogel matrix were successfully created and 
optimised in combination with thiol modified Hyaluronic acid acting as the cross linking agent. The 
hyperbranched structure provides multiple acrylate functional groups which allow more effective 
crosslinking to form a network structure with a higher crosslinking density so that to tailor the release 
profile of the bioactive molecules encapsulated 34. We applied this hydrogel as a drug delivery system to 
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inhibit the growth of the bacteria: S. aureus, P. aeruginosa and E. coli. After consideration of a number of 
antibacterial agents, silver sulfadiazine (SSD) was selected. SSD was loaded into these hydrogel samples 
successfully at varying concentration.  
A standard Kirby-bauer disk diffusion test 49  was adapted and used to evaluate SSD encapsulated 
hydrogels on their  bacterial inhibiting capability. Results were encouraging and showed that the growth 
of tested bacterial strains was thoroughly supressed when low concentrations of SSD were used. Upon 
analysis of these results and comparison of the zones of inhibition achieved from antibacterial agent 
concentrations of 0.0, 0.1, 1.0, 5.0% we noted that diffusion of SSD was a key factor in the zone of 
inhibition and that the direct contact and immediate areas surrounding it effectively inhibited growth of 
all three bacterial strains. Additionally, in an attempt to model and assess the release profile of this 
hydrogel system, release assays were performed in a PBS buffer over extended periods of time using SSD 
in the previously studied 0.0, 0.1, 1.0 and 5.0% w/v concentrations. This allowed for a detailed 
representation of the diffusion profile that can be expected from these hydrogels. The study demonstrated 
a burst release effect initially of SSD owing to the presence of particles on the hydrogel surface. The 
study also revealed that increased concentrations of SSD resulted in a faster rate of diffusion with higher 
SSD released over a more prolonged timeline.  
Finally a simple biological assay in the form of Alamar blue cell viability assay was performed to 
evaluate the effect of SSD loaded hydrogels on the survival and proliferation of ADSC’s. The test was 
performed at lowered concentrations as it became apparent that high (> 1.0% w/v) SSD concentration was 
toxic to cell viability. This test confirms that levels of SSD concentration above 1.0% w/v SSD in these 
hydrogels can be toxic to cells. This can in part be related to the initial burst release of SSD being 
overwhelming as the cell viability decreases initially (Day 1) for 1.0% w/v SSD and remains relatively 
stable through Day 3 and Day 7. The antibacterial assessment by means of a Disk Diffusion study of this 
hydrogel has confirmed that this low concentration (0.1 & 1.0% w/v) can have significant antimicrobial 
potency and can protect a wound from pathogenic development for extended time periods.  This study 
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also suggests that at lowered concentrations (0.1% & 1% w/v), these hydrogels can be used to inhibit 
bacteria without un-acceptable cell viability; however, burst release should be kept mindful.  
5. Conclusions 
In conclusion, a new dressing in the form of a composite hydrogel was successfully synthesised from the 
copolymer PEGDA-PEGMEMA and thiol modified hyaluronic acid as a cross linker, while silver based 
antimicrobial agent SSD was encapsulated. This new dressing demonstrates powerful antibacterial 
efficacy against three strains of the prime concern (S. aureus, P. aeruginosa and E. coli) in the fight 
against resistant bacteria. 
 Early cytotoxicity assessment of the dressing has revealed that increased concentrations of silver 
sulfadiazine adversely effects ADSC proliferation but that low concentrations can be used effectively 
without causing unacceptable cell mortality. However; burst release of SSD in contact with cells is an 
area for concern to keep mindful. Of these concentrations we determined that 1.0% w/v SSD 
concentration was most suitable for this application as it effectively inhibited bacterial growth of tested 
pathogens S. aureus, P. aeruginosa and E. coli while presenting an acceptable mortality to ADSC’s. Cell 
viability did highlight the concerns around the burst release effect and warrants this as an area of concern 
for future studies.  Furthermore, this 1% w/v formulation demonstrated a release profile with high burst 
rate in the beginning but a controlled slow release rate up as far as a 7 days tested period. We think that 
this release profile should be predictable and controllable given that release is governed by inter-diffusion 
of particles after initial burst release of surface SSD. This burst release aspect presents a design challenge 
for this hydrogel loading that we will seek overcome in future studies.  Further confirmation of the drug 
loading limitations will be optimised in a subsequent study. 
This research presents relevant information indicating that our new hydrogel system can be readily 
combined with current drugs/therapies (SSD) to prevent growth of bacteria. This partnership works well 
and our study into the systems release profile suggests a predictable, controllable release pattern. This 
24 
 
early study will be continued into further detailed optimisation and investigation into long term 
response/release and performance against infectious pathogens as well as detailed cell proliferation 
studies. 
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